



KNOWLEDGE SHARING AND CAPACITY BUILDING

- Ongoing advancement of analytical tools is critical to keep pace with the evolving control strategies and increasing complexity of ADCs and multi-specific biologics.
- Impurity control and testing remain vital as we design increasingly complex structures and multi-specifics with diverse building blocks and configurations.
- Potency assurance strategy can be optimized to reduce redundancy (e.g., antigen binding of mAb Intermediate) when supported by data.

CMC NORTH AMERICA 2025 BY THE NUMBERS



First-Time Attendees

34



Regulators Participated

7



Companies Represented

44



Countries Collaborated

6

Canada | Chile | Germany | Japan | South Korea | United States

CASSS RESOURCES

Looking for more past meeting content?

Speaker slides, roundtable notes, and video presentations can be accessed through **Papers and Presentations** and **CASSS On Demand** on our website. **www.casss.org**



